Nektar's $460M Raise: A High-Stakes Bet on a New Autoimmune Drug

SAN FRANCISCO, CA – February 13, 2026 – Nektar Therapeutics today confirmed the closing of a massive $460 million public offering, a move that dramatically reshapes its financial future and accelerates its ambitions in the competitive immunotherapy landscape. The capital infusion comes on the heels of a spectacular week for the company, which saw its stock price surge over 1,000% from its 52-week low, fueled by highly encouraging clinical trial data for its lead drug candidate.

The successful offering, which was upsized from its initial targets and saw underwriters fully exercise their option to purchase additional shares, signals powerful investor confidence. Nektar sold over 7.6 million shares of common stock at $58.00 per share, alongside a smaller number of pre-funded warrants. The move provides the clinical-stage biotech firm with a critical war chest to advance its promising, yet costly, drug pipeline.

A Financial Lifeline at a Cost

The gross proceeds of approximately $460 million provide a substantial runway for Nektar. Before this offering, the company reported having enough cash and investments to fund operations into the second quarter of 2027, based on a cash position of $270.2 million as of September 30, 2025. With quarterly operating expenses running around $43.5 million, this new capital significantly extends its financial horizon, providing the necessary backing for expensive late-stage clinical trials and manufacturing scale-up.

However, this financial fortification comes at a price for existing investors: significant dilution. The issuance of nearly 9 million new shares and warrants represents a substantial increase in the total shares outstanding, which stood at approximately 18.9 million in late 2025. This dilution, estimated at over 40%, explains the stock's brief dip in premarket trading after the offering was priced, a typical market reaction as ownership stakes are diluted.

Despite this, the market's overarching reaction has been overwhelmingly positive. The offering was strategically timed, capitalizing on a stock price that had rocketed from a low of $6.50 to over $70 in a matter of weeks. This allowed Nektar to raise a much larger sum at a more favorable price than would have been possible just a month ago, a classic biotech maneuver of turning scientific success into financial strength.

Fueling the Future of Immunotherapy

The excitement driving Nektar's resurgence stems from its lead candidate, rezpegaldesleukin, or REZPEG. The drug is a first-in-class regulatory T-cell stimulator designed to treat autoimmune diseases by correcting underlying immunological dysfunction rather than broadly suppressing the immune system.

Just days ago, Nektar released stellar 36-week maintenance data from its Phase 2b REZOLVE-AD study in patients with moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition. The results showed that REZPEG provided durable disease control with infrequent dosing. An impressive 83% of patients who achieved clear or almost clear skin during the initial treatment phase maintained that response with dosing as infrequent as once every quarter.

This potential for a quarterly dosing schedule is a key differentiator in a crowded market and a significant potential advantage for patient convenience. The FDA has already granted Fast Track designation to REZPEG for atopic dermatitis, as well as for another indication, severe alopecia areata, an autoimmune disease that causes hair loss. The company is now planning to initiate pivotal Phase 3 trials for REZPEG in atopic dermatitis later in 2026, a costly endeavor the new funding is earmarked to support. The pipeline also includes investigations into Type 1 diabetes for REZPEG and a separate oncology asset, NKTR-255, an IL-15 receptor agonist designed to boost the immune system's ability to fight cancer.

Investor Frenzy and a Volatile Ride

The journey of Nektar's stock (NASDAQ: NKTR) is a case study in the high-risk, high-reward nature of biotechnology investing. The recent positive clinical data acted as a powerful catalyst, transforming market sentiment and triggering a buying frenzy. The stock's dramatic climb reflects investor optimism that REZPEG could become a blockbuster drug.

Wall Street analysts have been quick to react, with multiple firms upgrading their ratings and price targets. William Blair shifted its rating from "market perform" to "outperform," while BTIG and HC Wainwright substantially raised their price targets to $151 and $165, respectively. The consensus points toward a belief that Nektar's technology is validated and that REZPEG has a strong chance of clinical and commercial success.

This public offering captures that momentum, converting market enthusiasm into tangible capital. It's a clear signal that, for now, investors are willing to overlook the risks of dilution and the long road to FDA approval in favor of the potential rewards from a truly innovative therapy.

Navigating a Crowded and Competitive Field

With its finances now secured for the foreseeable future, Nektar's focus shifts to execution. The path forward, however, is fraught with challenges. The atopic dermatitis market, valued at over $17 billion, is dominated by well-entrenched pharmaceutical giants. Sanofi and Regeneron's Dupixent, a biologic requiring injections every two weeks, generated over $11 billion in sales in 2024. The market also includes a host of JAK inhibitors from major players like Pfizer and AbbVie.

To succeed, Nektar must not only prove REZPEG's efficacy and safety in larger Phase 3 trials but also convincingly demonstrate its value proposition to doctors, patients, and payers. Its primary advantage appears to be the potential for significantly less frequent dosing, which could be a game-changing factor for patients managing a chronic condition. The capital raised this week provides the company with the essential resources to navigate this next critical phase of development and prove that its innovative approach to immunotherapy can deliver on its immense promise.